Abeona Therapeutics, Inc. (ABEO)
4.41
-0.02
(-0.45%)
USD |
NASDAQ |
Oct 19, 16:00
4.41
0.00 (0.00%)
After-Hours: 20:00
Abeona Therapeutics Enterprise Value : 126.56M for Oct. 16, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 16, 2026 | 126.56M |
| October 15, 2026 | 139.15M |
| October 14, 2026 | 122.55M |
| October 13, 2026 | 131.71M |
| October 12, 2026 | 153.45M |
| October 09, 2026 | 155.74M |
| October 08, 2026 | 156.89M |
| October 07, 2026 | 163.75M |
| October 06, 2026 | 159.75M |
| October 05, 2026 | 165.47M |
| October 02, 2026 | 160.89M |
| October 01, 2026 | 159.75M |
| September 30, 2026 | 173.48M |
| September 29, 2026 | 168.33M |
| September 28, 2026 | 175.77M |
| September 25, 2026 | 182.07M |
| September 24, 2026 | 183.78M |
| September 23, 2026 | 189.51M |
| September 22, 2026 | 206.10M |
| September 21, 2026 | 197.52M |
| September 18, 2026 | 191.79M |
| September 17, 2026 | 192.94M |
| September 16, 2026 | 180.35M |
| September 15, 2026 | 186.07M |
| September 14, 2026 | 183.78M |
| Date | Value |
|---|---|
| September 11, 2026 | 182.92M |
| September 10, 2026 | 186.64M |
| September 09, 2026 | 204.38M |
| September 08, 2026 | 207.82M |
| September 04, 2026 | 216.40M |
| September 03, 2026 | 212.40M |
| September 02, 2026 | 213.54M |
| September 01, 2026 | 215.26M |
| August 31, 2026 | 207.82M |
| August 28, 2026 | 211.82M |
| August 27, 2026 | 218.69M |
| August 26, 2026 | 216.97M |
| August 25, 2026 | 228.42M |
| August 24, 2026 | 219.84M |
| August 21, 2026 | 221.55M |
| August 20, 2026 | 214.11M |
| August 19, 2026 | 223.84M |
| August 18, 2026 | 225.56M |
| August 17, 2026 | 212.97M |
| August 14, 2026 | 215.54M |
| August 13, 2026 | 236.14M |
| August 12, 2026 | 299.95M |
| August 11, 2026 | 296.52M |
| August 10, 2026 | 299.38M |
| August 07, 2026 | 287.36M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Ultragenyx Pharmaceutical, Inc. | 2.337B |
| ACADIA Pharmaceuticals, Inc. | 2.409B |
| Alnylam Pharmaceuticals, Inc. | 30.68B |
| Anika Therapeutics, Inc. | 254.23M |
| Savara, Inc. | 771.40M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -20.19M |
| Revenue (Quarterly) | 11.38M |
| Total Expenses (Quarterly) | 31.57M |
| EPS Diluted (Quarterly) | -0.3539 |
| Gross Profit Margin (Quarterly) | 57.45% |
| Profit Margin (Quarterly) | -177.4% |
| Earnings Yield | -25.45% |
| Normalized Earnings Yield | -26.21 |